DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer

Information source: Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Lung Cancer

Intervention: methylprednisolone (Drug); fludeoxyglucose F 18 (Radiation); positron emission tomography (Procedure); computed tomography (Procedure)

Phase: N/A

Status: Withdrawn

Sponsored by: Ohio State University Comprehensive Cancer Center

Official(s) and/or principal investigator(s):
David Barker, MD, Principal Investigator, Affiliation: Ohio State University Comprehensive Cancer Center


The purpose of this study is to determine whether giving an anti-inflammatory medication (corticosteroid) prior to a positron emission tomography scan (PET) scan may reduce or eliminate false findings related to inflammation

Clinical Details

Official title: FDG PET/CT: Reducing False Positive Mediastinal Uptake by Premedicating With Methylprednisolone

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic

Primary outcome: Continuous standardized uptake values (SUV)

Detailed description: PRIMARY OBJECTIVES: I. To assess whether premedication with a corticosteroid may reduce false positive findings on fluorodeoxyglucose (fludeoxyglucose F 18 [FDG[) PET/computed tomography (CT) scans in lung cancer patients, by reducing radiotracer uptake in thoracic lymph nodes related to inflammation. OUTLINE: Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone intravenously (IV) and then undergo a second FDG PET/CT scan. After completion of study treatment, patients are followed up for 2 years.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patient undergoing initial staging of biopsy proven lung cancer (all cancer stages


- Undergone clinical FDG PET/CT scan within 14 days of enrollment

Exclusion Criteria:

- Prisoners

- Diabetic patients (on insulin, on oral hypoglycemic, or fasting glucose > 180 mg/dl)

- Serious infection within 14 days of enrollment

- Known hypersensitivity to methylprednisolone

- Viral skin lesions

- Immunocompromised ANC(absolute neutrophil count < 1000/microliter)

- Pregnant/nursing

- History of tuberculosis or systemic fungal disease

- History of steroid psychosis

- Current peptic ulcer disease or diverticulitis

- Corticosteroid use within 14 days of enrollment (including inhaled steroids)

Locations and Contacts

Additional Information


Starting date: June 2011
Last updated: February 8, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017